<DOC>
	<DOCNO>NCT02083783</DOCNO>
	<brief_summary>The purpose study determine whether TRI102 effective treatment Attention Deficit Hyperactivity Disorder ( ADHD ) child age 6-12 .</brief_summary>
	<brief_title>TRI102 Treatment Children With Attention Deficit Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description>A Phase 3 , randomize , double-blind , placebo-controlled , parallel group , multicenter , laboratory classroom study . After Screening Baseline evaluation , eligible subject enrol study enter open-label phase , dose-optimization phase . TRI102 take daily subject undergo dose optimization activity 5 week .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<criteria>Children age 6 12 year ADHD require pharmacologic treatment condition Other serious illness condition would put patient particular risk safety event would interfere treatment/assessment ADHD</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>